These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35438363)

  • 1. Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis.
    Xia F; Lyu J; Peng J; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):2837-2846. PubMed ID: 35438363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography.
    Wu L; Li M; Wang L; Yan H; Zhou Z; Fan J; Zhou Y; Gou K; Guo C; Wang Y; Zhang Z
    Sci Rep; 2023 Nov; 13(1):19946. PubMed ID: 37968276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab.
    Jang JH
    Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
    Bassiouny RM; Gaafar WM; El Nokrashy A; Abdelhameed AG; Attallah EA; Elgharieb AG; Bassiouny MR
    Eye (Lond); 2022 Nov; 36(11):2137-2143. PubMed ID: 34711941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
    Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
    Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.
    Zhang G; Yang M; Zeng J; Vakros G; Su K; Chen M; Li H; Tian R; Li N; Tang S; He H; Tan W; Song X; Zhuang R;
    Retina; 2017 Apr; 37(4):710-717. PubMed ID: 27529839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
    Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
    BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Arq Bras Oftalmol; 2017; 80(1):30-34. PubMed ID: 28380099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.
    Lyu J; Zhang Q; Chen CL; Xu Y; Ji XD; Li JK; Huang QJ; Zhao PQ
    Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1719-1725. PubMed ID: 28324112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect.
    Ji MH; Moshfeghi DM; Shields RA; Bodnar Z; Ludwig CA; Callaway NF; Orazi L; Amorelli GM; Lepore D
    Eur J Ophthalmol; 2021 Jul; 31(4):2135-2140. PubMed ID: 32722932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
    Jin E; Yin H; Li X; Zhao M
    Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.
    Chen Y; Wang S; Chen S; Chen X; Han L; Zhong Q; Zhang K
    BMC Ophthalmol; 2022 Jun; 22(1):271. PubMed ID: 35729540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
    Tong Q; Yin H; Zhao M; Li X; Yu W
    BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
    Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
    Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Recurrence of Plus Disease after Intravitreal Ranibizumab as a Primary Monotherapy for Severe Retinopathy of Prematurity.
    Arámbulo O; Dib G; Iturralde J; Brito M; Fortes Filho JB
    Ophthalmol Retina; 2018 Aug; 2(8):858-863. PubMed ID: 31047540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.